Meeting
2018 ASCO Annual Meeting
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.
Authors
Dirk Schadendorf
University Hospital Essen, Essen, Germany
Dirk Schadendorf , Axel Hauschild , Mario Santinami , Victoria Atkinson , Mario Mandalà , Vanna Chiarion-Sileni , James M. G. Larkin , Marta Nyakas , Caroline Dutriaux , Andrew Haydon , Laurent Mortier , Caroline Robert , Jacob Schachter , Ran Ji , Paola Aimone , Stephanie Manson , Richard Kefford , Reinhard Dummer , John M. Kirkwood , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01682083
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9590)
DOI
10.1200/JCO.2018.36.15_suppl.9590
Abstract #
9590
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).
First Author: Dirk Schadendorf
Poster
2018 ASCO Annual Meeting
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.
First Author: Reinhard Dummer
Poster
2022 ASCO Annual Meeting
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
First Author: Dirk Schadendorf
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis